Ibezapolstat not checked
Acurx Pharmaceuticals Inc. · ACX-362E
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 2
- “Single-arm trial to evaluate the safety and efficacy of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficile infection (CDI).”In the company’s words, NCT07513285 on ClinicalTrials.gov
- Other names
- ACX-362E
Other drugs for Clostridium Difficile Infection Recurrence
Coming up1
- 29 Sep 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 29 Sep 2027 | ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection | |
| Phase 2Completed | 3 Oct 2023 | ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026